Abstract:Twenty-five to thirty percent of patients with node-negative breast cancer are expected to relapse following surgery, therefore great efforts have been made to identify new prognostic markers that could be useful in defining patients for additional therapy. The expression of MMP-2 and MMP-9 has been associated with high potential of metastasis in several human carcinomas including breast cancer. In the present study we examined the prognostic value of immunoreactive MMP-2/MMP-9 protein in 270 consecutive lymph node negative cases who received radical mastectomy or modified radical mastectomy. Among the patients, 211 cases received adjuvant endocrine therapy and/or adjuvant chemotherapy. Using immunohistochemical assay, we found that 56.7% of the resected tumors were positive for MMP-2 whereas 59.6% of the samples were positive for MMP-9. χ 2 test demonstrated a significant direct association between MMP-2 and MMP-9 ( p < 0.001); positive immunostaining of MMP-2 was significantly related to higher tumor grade ( p < 0.001) and larger tumor size ( p =0.012); positive immunostaining of MMP-9 was significantly related to higher tumor grade ( p =0.002). In univariate analysis, using Cox-proportional hazard model we found MMP-2, MMP-9 and the co-expression of MMPs (MMP2/MMP9) were significantly associated with patients' relapse free survival ( p =0.016, 0.015 and 0.013 respectively) but not overall survival ( p =0.122, 0.320 and 0.091 respectively). Log-rank test also showed that MMP-2, MMP-9 or the co-expression of MMP2/MMP9 was unfavorable prognostic factor for relapse free survival but not overall survival. In subgroup analysis, we found MMPs were more prognostic for patients with no adjuvant treatment than for patients with adjuvant therapy. In multivariate analysis, using Cox-proportional hazard model we found co-expression of MMPs, larger tumor size and higher tumor grade were unfavorable for relapse free survival ( p =0.038, 0.007 and 0.015 for each). We concluded that MMP-2 and MMP-2 are unfavorable prognostic factors in breast cancer patients. They might be potential predictive factor for adjuvant systemic therapy. The co-expression of MMP-2 and MMP-9 has significantly prognostic value in node-negative patients.

The Relationship Between Expression of Matrix Metalloproteinase -2 in Trophoblastic Tumor and the Patients' Clinical Outcome

The Expression of Matrix Metalloproteinase (MMP-2) in Gestational Trophoblastic Disease (GTD)

[Expression and Significance of LMP2 and PPM1A in Gestational Trophoblastic Disease].

Expressions of MMP-7 and MMP-26 in gestational trophoblastic disease

Relationship of MMP-2mRNA Expression with Clinical Pathological Features and Prognosis in Gastric Cancer

Expression and clinical significance of MMP-2 and VEGF protein in epithelial ovarian tumors

Analysis of the Expression of Matrix Metalloproteinase and Tissue Inhibitor of Metalloproteinase in Gestational Trophoblastic Diseases

The Expression of Matrirx Metalloproteinase and Tissue Inhibitor of Metallo-proteinase in Endometrial Child Care

Relationship between matrix metalloproteinase-2 mRNA expression and clinicopathological and urokinase-type plasminogen activator system parameters and prognosis in human gastric cancer

Expression of Membrane Type-2 Matrix Metalloproteinase in Gastric Cancer Tissues and Its Correlation with Prognosis

Expressions of Thymidine Phorsphorylase and Matrix Metalloproteinase-2 in Gastric Carcinoma

Correlation and Prognostic Significance of MMP-2 and TFPI-2 Differential Expression in Pancreatic Carcinoma.

Expression of MMP-2 in Primary Carcinoma of Fallopian Tube

Clinical significance of matrix metalloproteinase-2 in endometrial cancer: A systematic review and meta-analysis.

The Study of Expression of Matrix Metalloproteinases-2 in Patients with Colorectal Cancer

Prognostic Value of Matrix Metalloproteinases (MMP-2 and MMP-9) in Patients with Lymph Node-Negative Breast Carcinoma

Relationships Between Expressions of MMP-2, MMP-9, TIMP-1 in Gastric Carcinoma and Pathological Characteristics and Prognosis

Expression of Matrix Metalloproteinase-2 in Lymph Node-Negative Breast Carcinoma and Its Clinical Value

Prognostic role and clinical significance of trophoblast cell surface antigen 2 in various carcinomas.

The Expression and Clinical Value of MMP-2 and MMP-9 in Hepatocellular Carcinoma

[Expression of Matrix Metalloproteinase-2 and Insulin-Like Growth Factor-1 in Gastric Carcinoma and Their Clinicopathological Significance].